{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T05:18:19Z","timestamp":1766207899775,"version":"3.48.0"},"reference-count":45,"publisher":"Pharmaceutical Society of Japan","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,12,18]]},"DOI":"10.1248\/bpb.b25-00578","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T22:08:38Z","timestamp":1766009318000},"page":"1932-1939","source":"Crossref","is-referenced-by-count":0,"title":["Effect of PEGylated Liposomalization of Oxaliplatin on the Gut Microbiota in Mice"],"prefix":"10.1248","volume":"48","author":[{"given":"Keisuke","family":"Mogi","sequence":"first","affiliation":[{"name":"Laboratory of Environmental Biochemistry, Division of Biological Sciences, Kyoto Pharmaceutical University, 5 Misasaginakauchi-cho, Yamashina-ku, Kyoto 607\u20138414, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Quality Control Department, Ako Kasei, Co., Ltd., 329 Sakoshi, Ako, Hyogo 678\u20130193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yasukawa","sequence":"additional","affiliation":[{"name":"Technical Development Department, Ako Kasei, Co., Ltd., 329 Sakoshi, Ako, Hyogo 678\u20130193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Uozumi","sequence":"additional","affiliation":[{"name":"Technical Development Department, Ako Kasei, Co., Ltd., 329 Sakoshi, Ako, Hyogo 678\u20130193, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiro","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, 1\u201378\u20131 Sho-machi, Tokushima 770\u20138505, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Nagasawa","sequence":"additional","affiliation":[{"name":"Laboratory of Environmental Biochemistry, Division of Biological Sciences, Kyoto Pharmaceutical University, 5 Misasaginakauchi-cho, Yamashina-ku, Kyoto 607\u20138414, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Barenholz Y. Doxil\u00ae<\/sup>\u2014the first FDA-approved nano-drug: lessons learned. J. Control Release.<\/i>, 160<\/b>, 117\u2013134 (2012).","DOI":"10.1016\/j.jconrel.2012.03.020"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Al-Hajeili M, Azmi AS, Choi M. Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Onco Targets Ther.<\/i>, 7<\/b>, 187\u2013192 (2014).","DOI":"10.2147\/OTT.S40705"},{"key":"3","unstructured":"3) Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res.<\/i>, 46<\/b>, 6387\u20136392 (1986)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, Gabizon A. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch. Dermatol.<\/i>, 136<\/b>, 1475\u20131480 (2000).","DOI":"10.1001\/archderm.136.12.1475"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol.<\/i>, 18<\/b>, 2938\u20132947 (2000).","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol. Assess.<\/i>, 12<\/b>, iii\u2013ix, xi-162 (2008).","DOI":"10.3310\/hta12150"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Zeuli M, Di Costanzo E, Sdrobolini A, Gasperoni S, Paoloni FP, Carpi A, Moscetti L, Cherubini R, Cognetti F. Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. Ann. Oncol.<\/i>, 12<\/b>, 1737\u20131741 (2001).","DOI":"10.1023\/A:1013562914125"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin. Oncol.<\/i>, 30<\/b> (<\/b>Suppl. 15)<\/b>, 5\u201313 (2003).","DOI":"10.1016\/S0093-7754(03)00399-3"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Shatunova S, Aktar R, Peiris M, Lee JYP, Vetter I, Starobova H. The role of the gut microbiome in neuroinflammation and chemotherapy-induced peripheral neuropathy. Eur. J. Pharmacol.<\/i>, 979<\/b>, 176818 (2024).","DOI":"10.1016\/j.ejphar.2024.176818"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Luan WW, Gu HW, Qiu D, Ding X, Liu PM, Hashimoto K, Yang JJ, Wang XM. Repeated administration of esketamine ameliorates mechanical allodynia in mice with chemotherapy-induced peripheral neuropathy: a role of gut microbiota and metabolites. Neurochem. Int.<\/i>, 185<\/b>, 105961 (2025).","DOI":"10.1016\/j.neuint.2025.105961"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Man S, Xie L, Liu X, Wang G, Liu C, Gao W. Diosgenin relieves oxaliplatin-induced pain by affecting TLR4\/NF-kappaB inflammatory signaling and the gut microbiota. Food Funct.<\/i>, 14<\/b>, 516\u2013524 (2023).","DOI":"10.1039\/D2FO02877H"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Stojanovska V, McQuade RM, Fraser S, Prakash M, Gondalia S, Stavely R, Palombo E, Apostolopoulos V, Sakkal S, Nurgali K. Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon. PLOS ONE<\/i>, 13<\/b>, e0198359 (2018).","DOI":"10.1371\/journal.pone.0198359"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Yuan W, Xiao X, Yu X, Xie F, Feng P, Malik K, Wu J, Ye Z, Zhang P, Li X. Probiotic therapy (BIO-THREE) mitigates intestinal microbial imbalance and intestinal damage caused by oxaliplatin. Probiotics Antimicrob. Proteins<\/i>, 14<\/b>, 60\u201371 (2022).","DOI":"10.1007\/s12602-021-09795-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Zhong S, Zhou Z, Liang Y, Cheng X, Li Y, Teng W, Zhao M, Liu C, Guan M, Zhao C. Targeting strategies for chemotherapy-induced peripheral neuropathy: does gut microbiota play a role? Crit. Rev. Microbiol.<\/i>, 45<\/b>, 369\u2013393 (2019).","DOI":"10.1080\/1040841X.2019.1608905"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Chrysostomou D, Roberts LA, Marchesi JR, Kinross JM. Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy. Gastroenterology<\/i>, 164<\/b>, 198\u2013213 (2023).","DOI":"10.1053\/j.gastro.2022.10.018"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via<\/i> a dual-targeting approach in a murine solid tumor model. J. Control. Release<\/i>, 137<\/b>, 8\u201314.","DOI":"10.1016\/j.jconrel.2009.02.023"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Abu-Lila A, Suzuki T, Doi Y, Ishida T, Kiwada H. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model. J. Control. Release<\/i>, 134<\/b>, 18\u201325.","DOI":"10.1016\/j.jconrel.2008.10.018"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Doi Y, Okada T, Matsumoto H, Ichihara M, Ishida T, Kiwada H. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model. Cancer Sci.<\/i>, 101<\/b>, 2470\u20132475 (2010).","DOI":"10.1111\/j.1349-7006.2010.01678.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Nakamura H, Abu Lila AS, Nishio M, Tanaka M, Ando H, Kiwada H, Ishida T. Intra-tumor distribution of PEGylated liposome upon repeated injection: no possession by prior dose. J. Control. Release<\/i>, 220<\/b>(<\/b>Pt A)<\/b>:406\u2013413 (2015).","DOI":"10.1016\/j.jconrel.2015.11.002"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Nishida K, Kashiwagi M, Shiba S, Muroki K, Ohishi A, Doi Y, Ando H, Ishida T, Nagasawa K. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity. Toxicol. Appl. Pharmacol.<\/i>, 337<\/b>, 76\u201384 (2017).","DOI":"10.1016\/j.taap.2017.10.006"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Mogi K, Kamiya I, Makino A, Hirao A, Abe R, Doi Y, Shimizu T, Ando H, Morito K, Takayama K, Ishida T, Nagasawa K. Liposomalization of oxaliplatin exacerbates the non-liposomal formulation-induced decrease of sweet taste sensitivity in rats. J. Pharm. Sci.<\/i>, 110<\/b>, 3937\u20133945 (2021).","DOI":"10.1016\/j.xphs.2021.07.004"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Ohishi A, Nishida K, Yamanaka Y, Miyata A, Ikukawa A, Yabu M, Miyamoto K, Bansho S, Nagasawa K. Oxaliplatin alters expression of T1R2 receptor and sensitivity to sweet taste in rats. Biol. Pharm. Bull.<\/i>, 39<\/b>, 578\u2013586 (2016).","DOI":"10.1248\/bpb.b15-00935"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kamimura Y, Kuwagaki E, Hamano S, Kobayashi M, Yamada Y, Takahata Y, Yoshimoto W, Morimoto H, Yasukawa T, Uozumi Y, Nagasawa K. Reproducible induction of depressive-like behavior in C57BL\/6J mice exposed to chronic social defeat stress with a modified sensory contact protocol. Life Sci.<\/i>, 282<\/b>, 119821 (2021).","DOI":"10.1016\/j.lfs.2021.119821"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Wang C, Qiu M, Wang S, Luo J, Huang L, Deng Q, Fang Z, Sun L, Gooneratne R. Gut-microbiota-derived butyric acid overload contributes to ileal mucosal barrier damage in late phase of chronic unpredictable mild stress mice. Int. J. Mol. Sci.<\/i>, 25<\/b>, 12998 (2024).","DOI":"10.3390\/ijms252312998"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Ma J, Piao X, Mahfuz S, Long S, Wang J. The interaction among gut microbes, the intestinal barrier and short chain fatty acids. Anim. Nutr.<\/i>, 9<\/b>, 159\u2013174 (2022).","DOI":"10.1016\/j.aninu.2021.09.012"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Jakobsson HE, Rodriguez-Pineiro AM, Schutte A, Ermund A, Boysen P, Bemark M, Sommer F, Backhed F, Hansson GC, Johansson ME. The composition of the gut microbiota shapes the colon mucus barrier. EMBO Rep.<\/i>, 16<\/b>, 164\u2013177 (2015).","DOI":"10.15252\/embr.201439263"},{"key":"27","unstructured":"27) Yoshimoto W, Takahata Y, Morito K, Takayama K, Morimoto H, Yasukawa T, Uozumi Y, Nagasawa K. Effect of ad libitum<\/i> ingestion of magnesium-rich mineral hard water on development of depressive-like phenotypes in mice exposed to chronic social defeat stress. Metallomics Res.<\/i>, 4<\/b>, reg01\u2013reg11 (2024)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Ericsson AC, Gagliardi J, Bouhan D, Spollen WG, Givan SA, Franklin CL. The influence of caging, bedding, and diet on the composition of the microbiota in different regions of the mouse gut. Sci. Rep.<\/i>, 8<\/b>, 4065 (2018).","DOI":"10.1038\/s41598-018-21986-7"},{"key":"29","unstructured":"29) Hufeldt MR, Nielsen DS, Vogensen FK, Midtvedt T, Hansen AK. Variation in the gut microbiota of laboratory mice is related to both genetic and environmental factors. Comp. Med.<\/i>, 60<\/b>, 336\u2013347 (2010)."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Surana NK, Kasper DL. Moving beyond microbiome-wide associations to causal microbe identification. Nature<\/i>, 552<\/b>, 244\u2013247 (2017).","DOI":"10.1038\/nature25019"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Iglesias-Aguirre CE, Garcia-Villalba R, Beltran D, Frutos-Lison MD, Espin JC, Tomas-Barberan FA, Selma MV. Gut bacteria involved in ellagic acid metabolism to yield human urolithin metabotypes revealed. J. Agric. Food Chem.<\/i>, 71<\/b>, 4029\u20134035 (2023).","DOI":"10.1021\/acs.jafc.2c08889"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Cenit MC, Sanz Y, Codoner-Franch P. Influence of gut microbiota on neuropsychiatric disorders. World J. Gastroenterol.<\/i>, 23<\/b>, 5486\u20135498 (2017).","DOI":"10.3748\/wjg.v23.i30.5486"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Evrensel A, Unsalver BO, Ceylan ME. Neuroinflammation, gut-brain axis and depression. Psychiatry Investig.<\/i>, 17<\/b>, 2\u20138 (2020).","DOI":"10.30773\/pi.2019.08.09"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Zhou LH, Liu XM, Feng XH, Han LO, Liu GD. Expression of \u03b1-gustducin in the circumvallate papillae of taste buds of diabetic rats. Acta Histochem.<\/i>, 111<\/b>, 145\u2013149 (2009).","DOI":"10.1016\/j.acthis.2008.05.007"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Yu M, Jia H, Zhou C, Yang Y, Zhao Y, Yang M, Zou Z. Variations in gut microbiota and fecal metabolic phenotype associated with depression by 16S rRNA gene sequencing and LC\/MS-based metabolomics. J. Pharm. Biomed. Anal.<\/i>, 138<\/b>, 231\u2013239 (2017).","DOI":"10.1016\/j.jpba.2017.02.008"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, Wang W, Tang W, Tan Z, Shi J, Li L, Ruan B. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav. Immun.<\/i>, 48<\/b>, 186\u2013194 (2015).","DOI":"10.1016\/j.bbi.2015.03.016"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Morito K, Yamagata M, Naka F, Kobayashi K, Ueda H, Morimoto H, Yasukawa T, Takayama K, Uozumi Y, Nagasawa K. Sub-chronic and mild social defeat stress exposure to C57BL\/6J mice increases visceral fat mass and causes accumulation of cholesterol and bile acids in the liver. Biochem. Biophys. Res. Commun.<\/i>, 702<\/b>, 149631 (2024).","DOI":"10.1016\/j.bbrc.2024.149631"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Komoto M, Asada A, Ohshima Y, Miyanaga K, Morimoto H, Yasukawa T, Morito K, Takayama K, Uozumi Y, Nagasawa K. Dextran sulfate sodium-induced colitis in C57BL\/6J mice increases their susceptibility to chronic unpredictable mild stress that induces depressive-like behavior. Life Sci.<\/i>, 289<\/b>, 120217 (2022).","DOI":"10.1016\/j.lfs.2021.120217"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Parker BJ, Wearsch PA, Veloo ACM, Rodriguez-Palacios A. The genus Alistipes<\/i>: gut bacteria with emerging implications to inflammation, cancer, and mental health. Front. Immunol.<\/i>, 11<\/b>, 906 (2020).","DOI":"10.3389\/fimmu.2020.00906"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Bangsgaard Bendtsen KM, Krych L, Sorensen DB, Pang W, Nielsen DS, Josefsen K, Hansen LH, Sorensen SJ, Hansen AK. Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB\/c mouse. PLOS ONE<\/i>, 7<\/b>, e46231 (2012).","DOI":"10.1371\/journal.pone.0046231"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Naseribafrouei A, Hestad K, Avershina E, Sekelja M, Linlokken A, Wilson R, Rudi K. Correlation between the human fecal microbiota and depression. Neurogastroenterol. Motil.<\/i>, 26<\/b>, 1155\u20131162 (2014).","DOI":"10.1111\/nmo.12378"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) M\u00fcller HE. Production and degradation of indole by gram-negative bacteria. Zentralbl. Bakteriol. Mikrobiol. Hyg. A<\/i>, 261<\/b>, 1\u201311 (1986).","DOI":"10.1016\/S0176-6724(86)80058-X"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Wang X, Eguchi A, Yang Y, Chang L, Wan X, Shan J, Qu Y, Ma L, Mori C, Yang J, Hashimoto K. Key role of the gut-microbiota-brain axis via<\/i> the subdiaphragmatic vagus nerve in demyelination of the cuprizone-treated mouse brain. Neurobiol. Dis.<\/i>, 176<\/b>, 105951 (2023).","DOI":"10.1016\/j.nbd.2022.105951"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Forsg\u00e5rd RA, Marrachelli VG, Korpela K, Frias R, Collado MC, Korpela R, Monleon D, Spillmann T, Osterlund P. Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats. Cancer Chemother. Pharmacol.<\/i>, 80<\/b>, 317\u2013332 (2017).","DOI":"10.1007\/s00280-017-3364-z"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Lin XB, Dieleman LA, Ketabi A, Bibova I, Sawyer MB, Xue H, Field CJ, Baracos VE, Ganzle MG. Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats. PLOS ONE<\/i>, 7<\/b>, e39764 (2012).","DOI":"10.1371\/journal.pone.0039764"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/12\/48_b25-00578\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T03:29:00Z","timestamp":1766201340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/12\/48_b25-00578\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00578","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"article-number":"b25-00578"}}